ANI製藥 ANIP 深 滬
等待開盤 07-18 09:30:00 美东时间
68.04
+1.440
+2.16%
華盛通- 最 高68.39
- 今 開66.37
- 成交量 40.12万股
- 最 低 65.96
- 昨 收 66.60
- 總市值 14.73亿
- 52周最高 76.9999
- 市盈率 靜 --
- 換手率 1.85%
- 52周最低 52.50
- 委 比 67.84%
- 總股本 2165.11万
- 歷史最高 86.96
- 量 比 1.17
- 振 幅 3.65%
- 歷史最低 0.80
- 每 手 1
- 風險率 4.34%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多ANIPLEX参展BilibiliWorld 2025，《命运-冠位指定》特别联动同步开启
2025年7月11日至13日，Bilibili World 2025在上海国家会展中心举行，索尼集团成员安尼普（上海）文化艺术有限公司（Aniplex Sha...
07-14 11:16
HC Wainwright & Co. Initiates Coverage On ANI Pharmaceuticals with Buy Rating, Announces Price Target of $84
HC Wainwright & Co. analyst Brandon Folkes initiates coverage on ANI Pharmaceuticals (NASDAQ:ANIP) with a Buy rating and announces Price Target of $84.
07-10 18:27
ANI Pharmaceuticals to Participate at Leerink Partners Therapeutics Forum: I&I and Metabolism on July 8th
The CEO of ANI Pharmaceuticals, Inc., Nikhil Lalwani, will host 1x1 meetings at the Leerink Partners Therapeutics Forum: I&I and Metabolism in Boston on July 8, 2025. The company, which focuses on developing innovative therapeutics in rare diseases, generics, and brands, announced the event in a press release.
07-02 10:50
ANI Pharmaceuticals Announces Presentation of New Preclinical Data
ANI Pharmaceuticals presented preclinical data on Purified Cortrophin Gel in a murine collagen-induced arthritis model at the 2025 EULAR Congress. The study showed that the gel reduced joint swelling and inflammatory cytokines without causing bone loss. This research, led by Maripat Corr, MD, and Nancy Lane, MD, provides new insights into the mechanism of action of Cortrophin Gel, a prescription drug for treating rheumatoid arthritis. The finding...
06-12 11:00
ANI Pharmaceuticals Highlights Financial Performance Amid Challenges
ANI Pharmaceuticals ( ($ANIP) ) has provided an update. ANI Pharmaceuticals has...
06-04 19:29
ANI Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference
ANI Pharmaceuticals' CEO, Nikhil Lalwani, will present at the 2025 Jefferies Global Healthcare Conference on June 4, 2025, at 2:35pm ET. A live and archived webcast will be available on the company’s website for 60 days. ANI is a biopharmaceutical company focused on rare disease therapeutics, generics, and brand medications. For investor inquiries, contact Lisa M. Wilson at lwilson@insitecony.com.
05-27 20:30
ANI Pharma Launches Phase 4 Trial to Test Cortrophin Gel Dosing for Gout Flares at Massachusetts General Hospital
ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ: ANIP) today announced the initiation of a Phase 4 clinical trial at Massachusetts General Hospital to compare the safety and efficacy of two dose levels (40 USPANI Pharmaceuticals, Inc.
05-22 18:51
ANI Pharmaceuticals Releases May 2025 Financial Presentation
ANI Pharmaceuticals ( ($ANIP) ) has shared an announcement. ANI Pharmaceuticals...
05-20 20:29
Cortrophin Demand Is Soaring For ANI Pharma, CEO Says Well-Positioned To Mitigate Potential Tariff Impact
ANI Pharmaceuticals Q1 revenue rose 43.4% to $197.12 million, EPS beat consensus, and 2025 guidance was raised on strong Cortrophin Gel and generics growth.
05-10 00:07
